A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT02998528 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

505

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL: Nivolumab
DRUG: Cisplatin
DRUG: Vinorelbine
DRUG: Gemcitabine
DRUG: Docetaxel
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Paclitaxel
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]